Walleye Trading LLC Immuno Gen, Inc. Transaction History

Walleye Trading LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $19,499 - $46,871	1,565 Added 13.91%	12,812 $379,000
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $1.14 Million - $1.6 Million	-80,619 Reduced 87.76%	11,247 $178,000
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $344,497 - $1.84 Million	91,866 New	91,866 $1.73 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $346,203 - $546,637	72,885 New	72,885 $541,000
Q1 2020 May 15, 2020	SELL	$2.12 - $6.8 $64,772 - $207,760	-30,553 Closed	0 $0

Q4 2019 Feb 14, 2020	SELL	$2.25 - $5.8 $165,631 - $426,961	-73,614 Reduced 70.67%	30,553 $156,000
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $171,357 - $261,667	77,188 Added 286.1%	104,167 $252,000
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $48,562 - $89,030	26,979 New	26,979 $59,000
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $17,472 - $42,847	-7,250 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $28,565 - $70,325	7,250 New	7,250 $35,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.